BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19
- PMID: 33915773
- PMCID: PMC8066210
- DOI: 10.3390/vaccines9040324
BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19
Abstract
BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2, which correlated with viral clearance and alleviated lung lesions in these mice after viral challenge.
Keywords: COVID-19; SARS-CoV-2; challenge study; efficacy; immunogenicity; mRNA vaccine.
Conflict of interest statement
A.H., Y.Y., and R.-R.J. are employees of Shanghai Fosun Pharmaceutical Industrial Development, Co. Ltd. (Shanghai, China); U.S. is a management board member and employees at BioNTech SE (Mainz, Germany); A.B.V. is an employee at BioNTech SE (Mainz, Germany); A.B.V. and U.S. are inventors on patents and patent applications related to RNA technology and COVID-19 vaccine and have securities from BioNTech SE; Fosun is co-developing BNT162b2 with BioNTech for the greater China market; C.Q., Y.Q., and H.Z. are employees of Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, and received compensation from Shanghai Fosun Pharmaceuticals to conduct the animal challenge work; no other relationships or activities have influenced the submitted work.
Figures

References
-
- Yang X.-H., Deng W., Tong Z., Liu Y.-X., Zhang L.-F., Zhu H., Gao H., Huang L., Liu Y.-L., Ma C.-M., et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. Comp. Med. 2007;57:450–459. - PubMed
-
- Kirchdoerfer R.N., Wang N., Pallesen J., Wrapp D., Turner H.L., Cottrell C.A., Corbett K.S., Graham B.S., McLellan J.S., Ward A.B. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci. Rep. 2018;8:15701. doi: 10.1038/s41598-018-34171-7. - DOI - PMC - PubMed
-
- Pallesen J., Wang N., Corbett K.S., Wrapp D., Kirchdoerfer R.N., Turner H.L., Cottrell C.A., Becker M.M., Wang L., Shi W., et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. USA. 2017;114:E7348–E7357. doi: 10.1073/pnas.1707304114. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous